We would appreciate it if you could complete our website survey, open until 28 November 2025.
This item is authorised by the following title:
For application, saving and transitional provisions relating to the repeal of this instrument, see section 26 of the National Health (Growth Hormone Program) Special Arrangement 2025.
National Health (Growth Hormone Program) Special Arrangement Amendment Instrument 2024 (No. 1) (F2024L01245)
National Health Legislation Amendment (Extension of Closing the Gap – PBS Co-payment Program) Instrument 2024 (F2024L00803)
National Health Legislation (Repeal and Consequential Amendments) Instrument 2024 (F2024L00412)
National Health (Growth Hormone Program) Special Arrangement Amendment Instrument 2023 (No. 2) (F2023L01336)
National Health (Growth Hormone Program) Special Arrangement Amendment Instrument 2023 (No. 1) (F2023L00167)
National Health (Growth Hormone Program) Special Arrangement Amendment (Mecasermin and Somatrogon) Instrument 2022 (F2022L01250)
National Health (Growth Hormone Program) Special Arrangement Amendment Instrument 2022 (No. 1) (F2022L01307)
National Health (Growth Hormone Program) Special Arrangement Amendment Instrument 2021 (No. 2) (F2021L00664)
National Health (Growth Hormone Program) Special Arrangement Amendment Instrument 2021 (No. 1) (F2021L00528)
National Health (Growth Hormone Program) Special Arrangement Amendment Instrument 2020 (No. 1) (PB 6 of 2020) (F2020L00071)
National Health (Growth Hormone Program) Special Arrangement Amendment Instrument 2019 (No. 3) (PB 109 of 2019) (F2019L01679)
For application, saving and transitional provisions relating to the repeal of this instrument, see section 26 of the National Health (Growth Hormone Program) Special Arrangement 2025.